Is nesiritide still available?

On February 5, 2018, the Food and Drug Administration reported that Janssen Pharmaceuticals was discontinuing the manufacture of nesiritide, the recombinant human B-type natriuretic peptide. On June 20, 2018, the American Society of Hospital Pharmacists announced a current nesiritide drug shortage.

What is drug BNP?

Brain natriuretic peptide (BNP) is predominantly a cardiac ventricular hormone that promotes natriuresis and diuresis, inhibits the renin-angiotensin-aldosterone axis, and is a vasodilator. Plasma BNP levels are raised in essential hypertension, and more so in left ventricular (LV) hypertrophy and heart failure.

Is nesiritide used in congestive heart failure?

Nesiritide (Natrecor) is a recombinant form of human B-type (brain) natriuretic peptide that has beneficial vasodilatory, natriuretic, diuretic and neurohormonal effects. The drug is administered intravenously for the management of patients with decompensated congestive heart failure (CHF).

What drug class is nesiritide?

Nesiritide, a recombinant human B-type natriuretic peptide, is the first in a new drug class for the treatment of decompensated heart failure. The drug binds to receptors in the vasculature, kidney, adrenal gland, and brain, and overcomes resistance to endogenous BNP present in patients with CHF.

What type of drug is milrinone?

Milrinone is a vasodilator that is used as a short-term treatment for life-threatening heart failure.

Where does BNP come from?

BNP was initially called brain natriuretic peptide because it was first found in brain tissue (and to distinguish it from a similar protein made in the atria, or upper chambers, of the heart, termed ANP). BNP is actually produced primarily by cells in the left ventricle of the heart.

Does nesiritide increase cardiac output?

Nesiritide may promote diuresis because of a direct natriuretic action, increased cardiac output, and/or decreased aldosterone levels. In patients hospitalized for decompensated HF, nesiritide improves symptoms and is well tolerated.

How long will I take trimetazidine?

In conclusion, treatment with trimetazidine added to the usual treatment for up to 18 months was well tolerated and induced functional improvement in patients with ischaemic dilated cardiomyopathy. Trimetazidine treatment was associated with a significant improvement of LV function and the remodelling process.